Omega 3 Supplementation and Ocular Surface Disease in Glaucoma
| Status: | Completed |
|---|---|
| Conditions: | Ocular |
| Therapuetic Areas: | Ophthalmology |
| Healthy: | No |
| Age Range: | 18 - Any |
| Updated: | 4/2/2016 |
| Start Date: | April 2012 |
| End Date: | December 2013 |
Omega-3 Fatty Acid Nutritional Supplementation in the Treatment of Ocular Surface Disease Associated With Intraocular Pressure-Lowering Medications
Ocular surface disease (OSD) is a significant health problem that affects more than 10
million persons in the United States alone. OSD is highly prevalent among medically treated
patients with glaucoma and is associated with the number of intraocular pressure
(IOP)-lowering medications used.
The purpose of this study is to determine the potential effectiveness of anoritega-3 fatty
acid nutritional supplement in the treatment of ocular surface disease associated"with the
use of glaucoma eye drops
million persons in the United States alone. OSD is highly prevalent among medically treated
patients with glaucoma and is associated with the number of intraocular pressure
(IOP)-lowering medications used.
The purpose of this study is to determine the potential effectiveness of anoritega-3 fatty
acid nutritional supplement in the treatment of ocular surface disease associated"with the
use of glaucoma eye drops
Description of procedures/methods:
BASELINE VISIT Once the treating ophthalmologist has made the diagnosis of OSD, subjects
will be asked to participate in the research study. Informed consent will be obtained for
all subjects willing to participate in the study. Afterwards, the treating ophthalmologist
will administer a dry eye questionnaire to each subject. After completion of the
questionnaire, subjects will be given 90-day supply of the study drug/placebo. Based on a
pre-determined randomization list, each subjects will be randomized to receive either the
study medication (TheraTears nutritional supplementation) or a placebo drug (olive oil
capsules). All subjects will be instructed to continue using artificial lubrication as
needed while taking part in this study.
We hypothesize that therapy with an oral fish oil nutritional supplement containing 450mg
EPA, 300 mg DHA, and 1000 mg flaxseed oil (TheraTears Nutrition; Advanced Vision Research,
Woburn, MA) will decrease OSD-related symptoms as well as clinical markers associated with
OSD (Schirmer test values, positive vital staining with lissamine green, fluorescein tear
break-up time, and tear film osmolarity) when compared to administration of placebo.
FOLLOW-UP VISIT Approximately 90 days after the baseline visit, subjects are scheduled to
come to the clinic for their routine• eye check. At that visit, subject's O.SD will be
re-assessed by the same examination techniques as the baseline visit. After the examination,
the questionnaire will be administered for a second time. The study drug will be
discontinued at that visit and standard therapy for the subject's OSO, as deemed necessary
by the treating ophthalmologist, will be instituted.
Statement of duration of subject participation:
Subject will be in the study for 3 months. There will be two visits, one is the baseline and
second is the follow-up visit. All visits will coincide with their regular clinic visit. The
total hours of study participation is no more than 2 hours.
BASELINE VISIT Once the treating ophthalmologist has made the diagnosis of OSD, subjects
will be asked to participate in the research study. Informed consent will be obtained for
all subjects willing to participate in the study. Afterwards, the treating ophthalmologist
will administer a dry eye questionnaire to each subject. After completion of the
questionnaire, subjects will be given 90-day supply of the study drug/placebo. Based on a
pre-determined randomization list, each subjects will be randomized to receive either the
study medication (TheraTears nutritional supplementation) or a placebo drug (olive oil
capsules). All subjects will be instructed to continue using artificial lubrication as
needed while taking part in this study.
We hypothesize that therapy with an oral fish oil nutritional supplement containing 450mg
EPA, 300 mg DHA, and 1000 mg flaxseed oil (TheraTears Nutrition; Advanced Vision Research,
Woburn, MA) will decrease OSD-related symptoms as well as clinical markers associated with
OSD (Schirmer test values, positive vital staining with lissamine green, fluorescein tear
break-up time, and tear film osmolarity) when compared to administration of placebo.
FOLLOW-UP VISIT Approximately 90 days after the baseline visit, subjects are scheduled to
come to the clinic for their routine• eye check. At that visit, subject's O.SD will be
re-assessed by the same examination techniques as the baseline visit. After the examination,
the questionnaire will be administered for a second time. The study drug will be
discontinued at that visit and standard therapy for the subject's OSO, as deemed necessary
by the treating ophthalmologist, will be instituted.
Statement of duration of subject participation:
Subject will be in the study for 3 months. There will be two visits, one is the baseline and
second is the follow-up visit. All visits will coincide with their regular clinic visit. The
total hours of study participation is no more than 2 hours.
Inclusion Criteria:
- Age > 18 years
- Typical symptoms of dry eye (photophobia, burning, foreign body sensation, blurred
vision improved with blinking)
- OSDI score > 12
- Schirmer Test with Anesthesia < 8 mm/5 minutes
- Fluorescein tear break-up time < 8 seconds
- No current use of dry eye treatment (except artificial lubrication)
Exclusion Criteria:
- Infectious keratoconjunctivitis or inflammatory disease unrelated to dry eye or
topical glaucoma medication use
- Patients with severe tear deficiency (defined as Schirmer tes <5 mm/5 min)
- Concomitant ocular pathology
- History of ocular surgery
- Eyelid or eyelash abnormalities
- Alteration of the nasolacrimal apparatus
- Treatment with drugs affecting tearing
- Treatment with vitamin supplements
- Concomitant ocular therapies
- Topical ophthalmic steroids taken during the 4 weeks before the study
- Pregnant/breast-feeding women
- Women who may be pregnant at the baseline visit or may become pregnant during the 90
days of therapy
- Diabetes
- History of fish and/or shellfish allergy or hypersensitivity
We found this trial at
1
site
Click here to add this to my saved trials
